2,4-Diamino-5-benzyl-6-methyl-pyrimidin | 18588-42-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2,4-Diamino-5-benzyl-6-methyl-pyrimidin
• 英文别名: 5-Benzyl-6-methyl-pyrimidine-2,4-diamine；5-benzyl-6-methylpyrimidine-2,4-diamine
• CAS: 18588-42-6
• 化学式: C₁₂H₁₄N₄
• 分子量: 214.27
• InChiKey: XUVFLMZAMCGKSH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  77.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,4-Diamino-5-benzyl-6-methyl-pyrimidin 在 硫酸 、 potassium nitrate 作用下， 生成 6-甲基-5-(4-硝基苄基)嘧啶-2,4-二胺
  参考文献：
  名称：

  2,4-Diaminopyrimidines as Antimalarials. II. 5-Benzyl Derivatives

  摘要：

  DOI：

  10.1021/ja01152a059
• 作为产物：
  描述：

  2-acetyl-3-phenylpropanenitrile 以 甲醇 、 乙醚 为溶剂， 生成 2,4-Diamino-5-benzyl-6-methyl-pyrimidin
  参考文献：
  名称：

  Selective synthesis of fluorinated benzyl- or phenylpyrimidines from the heterocyclisation of α-trifluoroacetylarylpropanenitriles

  摘要：

  Some 5-benzyl-6-trifluoromethyl-2,4-diaminopyrimidines analogous to trimethoprim and 6-aryl -5-trifluoroethyl-2,4-diaminopyrimidines analogous to pyrimethamine were prepared from the same synthons, trifluoromethylated P-ketonitriles. The heterocyclisation between enol ether of beta-ketonitrile and guanidine leading to these compounds was studied. These fluorinated novel compounds were tested for their in vitro activity against Toxoplasma gondii, a widespread apicomplexan protozoa responsible for congenital toxoplasmosis and cerebral toxoplasmosis in immunocompromised patients. (c) 2007 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.jfluchem.2007.05.014

文献信息

• Pyridopyrimidinone Inhibitors of PI3Kalpha
  申请人：Baik Tae-Gon

  公开号：US20110237608A1

  公开（公告）日：2011-09-29

  The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.

  本发明涉及式I的化合物及其药学上可接受的盐或溶剂，以及制备和使用这些化合物的方法。
• Pyridopyrimidinone inhibitors of pi3kalpha
  申请人：Baik Tae-Gon

  公开号：US20090062274A1

  公开（公告）日：2009-03-05

  The invention is directed to Compounds of Formula I and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.

  本发明涉及公式I的化合物及其药学上可接受的盐或溶剂化物，以及制备和使用这些化合物的方法。
• Pyridopyrimidinone Inhibitors of Pl3Kalpha
  申请人：Baik Tae-Gon

  公开号：US20090270430A1

  公开（公告）日：2009-10-29

  The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.

  本发明涉及化合物I式及其药学上可接受的盐或溶剂化物，以及制备和使用这些化合物的方法。
• METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF P13K ALPHA
  申请人：Lamb Peter

  公开号：US20100209420A1

  公开（公告）日：2010-08-19

  The present invention provides methods of treating cancer by administering a compound of Formula I, optionally as a pharmaceutically acceptable salt, solvate and/or hydrate thereof, in combination with other cancer treatments. (Formula I)

  本发明提供了一种通过与其他癌症治疗方法联合使用的方式，给予公式I化合物（可选择其作为药用盐，溶剂或水合物）来治疗癌症的方法。（公式I）
• PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER
  申请人：Buhr Chris A.

  公开号：US20100150827A1

  公开（公告）日：2010-06-17

  The invention is directed to a Compound of Formula I, II, or III. The invention provides compounds that inhibit, regulate, and/or modulate PI3K that are useful in the treatment of hyperproliferatives diseases, such as cancer.

  本发明涉及公式I、II或III的化合物。本发明提供了抑制、调节和/或调节PI3K的化合物，这些化合物在治疗增殖性疾病，如癌症方面非常有用。